ON06 | IDENTIFYING NURSING TRAINING NEEDS FOR THE MANAGEMENT OF BISPECIFIC DRUGS AND PATIENT FOLLOW‐UP IN ONCO‐HEMATOLOGY UNITS: A NON‐INTERVENTIONAL, E‐SURVEY BELL STUDY

Documenti analoghi

• 874 | TIME TOXICITY IN THE ERA OF BISPECIFIC ANTIBODY TREATMENT IN RELAPSED/REFRACTORY NON‐HODGKIN LYMPHOMA: CONCEPT ELICITATION WITH HEMATOLOGISTS AND PATIENT PERSPECTIVES
  di: A. Major, et al.
  Pubblicazione: (2025)
• 297 | CAUSES OF EXCESS NON‐LYMPHOMA DEATH IN 60,000 PATIENTS WITH DLBCL DIAGNOSED IN ENGLAND, 1997–2020: AN OBSERVATIONAL COHORT STUDY WITH UP TO 25 YEARS FOLLOW‐UP
  di: A. Challenger, et al.
  Pubblicazione: (2025)
• ON08 | EDUCATIONAL NEEDS OF SWISS PATIENTS WITH HEMATOLOGICAL DISEASES: FOCUS ON KNOWLEDGE REGARDING HEMATOLOGY LABORATORY RESULTS AND BIOMEDICAL CONCEPTS
  di: C. Dedieu, et al.
  Pubblicazione: (2025)
• ON05 | ADVANCING NURSING KNOWLEDGE OF CD20‐CD3 BISPECIFIC ANTIBODY TREATMENT FOR B‐CELL NON‐HODGKIN LYMPHOMA IN AUSTRALIA: A SCOPING REVIEW OF ADVERSE EVENTS TO INFORM PRACTICE
  di: E. Knights, et al.
  Pubblicazione: (2025)
• 707 | CLINICAL OUTCOMES WITH BISPECIFIC ANTIBODIES IN THE MANAGEMENT OF SECONDARY CENTRAL NERVOUS SYSTEM LYMPHOMA
  di: N. K. Dave, et al.
  Pubblicazione: (2025)